Gainers

• Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million.
• Regencell Bioscience (NASDAQ:RGC) stock moved upwards by 35.79% to $8.27. The market value of their outstanding shares is at $3.0 billion.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock increased by 33.18% to $0.12.
• Streamex (NASDAQ:STEX) shares moved upwards by 27.01% to $1.08. The market value of their outstanding shares is at $88.6 million.
• SeaStar Medical Holding (NASDAQ:ICU) stock rose 26.02% to $4.62. The company's market cap stands at $14.6 million.
• Regentis Biomaterials (AMEX:RGNT) shares increased by 24.64% to $4.4. The market value of their outstanding shares is at $24.8 million.

Losers

• Curis (NASDAQ:CRIS) shares fell 18.3% to $0.43 during Wednesday's regular session. The market value of their outstanding shares is at $20.3 million.
• Creative Medical Tech (NASDAQ:CELZ) shares fell 15.83% to $1.22. The market value of their outstanding shares is at $5.3 million.
• Eloxx Pharma (NASDAQ:ELOX) stock decreased by 14.63% to $11.85. The company's market cap stands at $47.6 million.
• SL Science Holding (NASDAQ:SLBT) stock fell 12.74% to $4.18. The company's market cap stands at $2.6 billion.
• XTL Biopharmaceuticals (NASDAQ:XTLB) stock decreased by 11.73% to $2.41. The market value of their outstanding shares is at $6.4 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) stock declined by 11.61% to $5.83. The market value of their outstanding shares is at $17.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.